Name:	aptx_NumberOfOptionsToAcquireMolecules
Namespace Prefix:	aptx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

It represents payment for option exercise fee.

No definition available.

Name:	aptx_PaymentOfOptionExerciseFee
Namespace Prefix:	aptx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The amount that was reimbursed under the research collaboration agreement.

No definition available.

Name:	aptx_ResearchAndDevelopmentExpenseReimbursementAmount
Namespace Prefix:	aptx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

The percentage of research and development expenses that are reimbursable under the research collaboration agreement.

No definition available.

Name:	aptx_ResearchAndDevelopmentExpenseReimbursementPercentage
Namespace Prefix:	aptx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054

Name:	us-gaap_CapitalizedContractCostNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

No definition available.

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373